Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation

  1. Benito-Villalvilla, C.
  2. de la Rocha-Muñoz, A.
  3. López-Abente, J.
  4. Eggel, A.
  5. Bottoli, I.
  6. Severin, T.
  7. Woisetschläger, M.
  8. Palomares, O.
Aldizkaria:
Allergy: European Journal of Allergy and Clinical Immunology

ISSN: 1398-9995,  0105-4538

Argitalpen urtea: 2023

Alea: 78

Zenbakia: 4

Orrialdeak: 1060-1072

Mota: Artikulua

DOI: 10.1111/ALL.15567 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus